Ondine Biomedical Inc.
OBIMF
$0.14
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 1.53M | 1.49M | 1.35M | 1.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 1.53M | 1.49M | 1.35M | 1.21M |
| Cost of Revenue | 540.80K | 532.70K | 531.10K | 507.60K | 482.10K |
| Gross Profit | 1.04M | 995.40K | 962.70K | 845.90K | 724.10K |
| SG&A Expenses | 8.01M | 7.97M | 8.03M | 7.27M | 6.48M |
| Depreciation & Amortization | 390.40K | 387.90K | 390.60K | 398.10K | 404.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.87M | 17.16M | 15.66M | 13.87M | 11.99M |
| Operating Income | -17.29M | -15.63M | -14.17M | -12.51M | -10.78M |
| Income Before Tax | -17.12M | -15.42M | -13.92M | -12.26M | -10.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.12 | -15.42 | -13.92 | -12.26 | -10.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.12M | -15.42M | -13.92M | -12.26M | -10.54M |
| EBIT | -17.29M | -15.63M | -14.17M | -12.51M | -10.78M |
| EBITDA | -16.99M | -15.41M | -14.02M | -12.37M | -10.64M |
| EPS Basic | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 1.49B | 1.29B | 1.10B | 990.18M | 881.95M |
| Average Diluted Shares Outstanding | 1.49B | 1.29B | 1.10B | 990.18M | 881.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |